Signals, Powered By EquityPandit
Glenmark Pharmaceuticals Europe Ltd, has received approval for an inhaled respiratory product in Nordic countries, including Sweden, Denmark, Norway, Finland and Iceland.
In a BSE filing, Glenmark Pharma stated, the company “has successfully closed the decentralized registration procedure for generic Seretide Accuhaler in the Nordic region.”
Further it stated that, it is the Glenmark’s first inhaled respiratory product approval, in Europe and commercialization of the product will depend on the national approval as well as substitution and pricing approvals.
